Venus concept receives 510(k) clearance for use of its ai.me™ next generation robotic technology for fractional skin resurfacing

Venus concept inc. (“venus concept” or the “company”) (nasdaq: vero), a global medical aesthetic technology leader, today announced that it has received a 510(k) clearance from the u.s. food and drug administration (“fda”) to market its ai.me next generation robotic technology for fractional skin resurfacing.
VERO Ratings Summary
VERO Quant Ranking